Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Where Eli Lilly starts to really separate itself from Novo Nordisk is in other markets. For example, over the summer Lilly's Alzheimer's drug received approval from the FDA. More recently ...

Eli Lilly (LLY) has enjoyed a successful run the ... Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London on March 8, 2024. (Reuters/Hollie Adams/File Photo) · REUTERS / Reuters ...

Novo Nordisk and Eli Lilly are expanding beyond obesity drugs, targeting new markets for long-term growth. Eli Lilly's stock shows stronger technical momentum, trading above key moving averages ...

Amycretin has some intriguing results in obesity Amycretin, an experimental Novo Nordisk obesity pill that targets both amylin and GLP-1 receptors, spurred significant weight loss in a Phase 1 ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...

Access to diabetes care in lower-income countries still lags for children, despite efforts from insulin makers.

Novo Nordisk had a big head start in the race to dominate the weight-loss market. But Eli Lilly LLY-0.56%decrease; red down pointing triangle is catching up fast. The two companies’ divergent ...

Shelby Knowles / Bloomberg / Getty Images Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study. Zepbound patients lost an ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...